The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InCureVac SE has filed a lawsuit against Moderna Inc., alleging the infringement of 10 patents related to the Spikevax COVID-19 vaccines. The German firm claims that Moderna utilized its proprietary mRNA compositions and lipid nanoparticle technology without authorization to develop its global vaccine portfolio. CureVac is seeking reasonable royalties from Moderna's global Spikevax sales, which have surpassed $47.7 billion to date. This legal action highlights the intensifying battle over intellectual property rights within the biotechnology sector. While the lawsuit poses a significant financial risk to Moderna, legal experts note that biotech patent litigation is typically a protracted process. Investors are closely monitoring the case as it could impact Moderna's long-term profitability and royalty obligations.